CHAEUM Premium

Product Overview

THE CHAEUM® Premium No.1, No.2, No.3 and No.4 are four cross-linked hyaluronic acid (HA) dermal fillers in HUGEL’s Korean THE CHAEUM range, with ACROSS identified in Korean product-permit records. For professional product comparison, the numbered formulations differ principally in relative gel firmness and supplied needle gauge, progressing from No.1 to No.4. Referenced commercial packs contain two 1.1 mL prefilled syringes with 0.3% lidocaine. Published HA concentration for No.1 is inconsistent across distributors; buyers should confirm the original label before selecting that option. Authorized uses and pack details depend on the exact market-specific product.

Key Features

• Four differentiated HA gels Premium No.1 through No.4 progress from a softer fine-line profile to firmer formulations positioned for deeper folds and facial volume support.
• Monophasic cross-linked formulation The range is described as a cohesive, single-phase HA gel family with different cross-linking and viscoelastic characteristics.
• Lidocaine 0.3% The four Premium presentations are listed with 0.3% (3 mg/mL) lidocaine, a local anesthetic included in the gel formulation.
• Two-syringe packaging The referenced commercial packs contain two 1.1 mL prefilled syringes and four needles, with needle gauge varying by Premium number.
• HUGEL quality process HUGEL describes eight-stage dialysis in THE CHAEUM® manufacturing process to control residual BDDE, the HA cross-linking agent. This is a manufacturer-reported quality characteristic, not a claim of zero residuals.

Composition & Specifications

All numerical specifications refer to the versions documented in the linked sources. Packaging and authorized indications must be checked against the actual destination-market product and Instructions for Use.

How It Works

Hyaluronic acid is a naturally occurring component of the extracellular matrix with water-binding properties. Cross-linking joins HA chains into a more cohesive gel, allowing dermal fillers to provide temporary physical support in soft tissue. The gel's mechanical behavior depends on its formulation, including cross-linking and rheological characteristics, rather than HA concentration alone.

The four THE CHAEUM® Premium products are described as a progression of gels with increasing relative firmness and different correction profiles. HUGEL also describes an eight-stage dialysis process to reduce residual BDDE in THE CHAEUM® fillers. These are manufacturer-described material properties; actual clinical outcomes, safety considerations and indications are governed by the approved labeling for the specific product and market.

Available Variants

For product selection, compare the four numbered gels by their manufacturer-described relative firmness, HA concentration information and accessory specifications. Published application descriptions are not a substitute for local authorized indications or professional instructions for use.

*Published brand-brochure and multiple supplier specifications list Premium No.1 at 24 mg/mL, while one JDBIO listing states 20 mg/mL. Verify the exact supplied No.1 product against its official carton and IFU. Listed applications summarize the product range's commercial positioning and are not universal regulatory approvals.

Professional Product Selection Considerations

When reviewing THE CHAEUM Premium options, first match the full variant name—No.1, No.2, No.3 or No.4—to the gel profile and the accessories listed on the original carton. The four numbers identify different formulations; the needle gauge alone does not establish an approved injection site, technique or indication.

• Confirm the exact HA concentration. No.1 has conflicting published specifications of 20 mg/mL and 24 mg/mL. Verify the specific lot and market label instead of assuming that a reseller listing applies to all inventory.
• Check the pack configuration. The referenced presentation is 2 × 1.1 mL prefilled syringes with four needles per box, but market-specific packaging and included accessories should be confirmed.
• Match the product and destination market. Confirm lidocaine content, original packaging, expiration date, current instructions for use and applicable authorization for the specific variant.
• Review handling requirements. Distributors report 2–25°C storage; confirm the manufacturer-approved instructions on the supplied carton before transport or stock management.

Product information supports professional product identification and comparison only. TEOSQUARE prices, stock levels and purchasing options are provided separately by the store interface; no market-wide approval or clinical interchangeability is implied.

Storage & Handling

Specialist distributor documentation lists unopened storage at 2–25°C, protected from direct sunlight and freezing. The latest manufacturer-issued Instructions for Use for each exact SKU were not independently retrieved; always follow the storage conditions on the original carton and the approved labeling supplied with the product.

THE CHAEUM® Premium products are sterile, single-use injectable medical devices intended for appropriately qualified healthcare professionals. Confirm product identity, packaging integrity, expiration date and relevant contraindications before professional use. As with other HA dermal fillers, serious adverse events, including vascular complications, are possible.

Frequently Asked Questions

Product Information Sources

• HUGEL — Official THE CHAEUM® Brand, Approved-Purpose Overview and Manufacturing Process
• HUGEL — Product Portfolio Statement Including Four THE CHAEUM Premium Formulations (July 2026)
• Korean Medical Device Permit Data — ACROSS, Permit No. 20-527 (Secondary Registry)
• JDBIO — THE CHAEUM Premium No.1 Listing (20 mg/mL; conflicting specification)
• JMC Derma — THE CHAEUM Premium No.1 Listing (24 mg/mL; conflicting specification)